MBX
MBX Biosciences, Inc.
53.60$
-3.2%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | -10.5% | -16.5% | +349.1% | -4.9% | -8.4% | -5.9% | +72.8% | -3.7% | +17.5% | -3.7% | |
| – | – | -12.9% | -19.1% | +378.2% | -4.9% | -8.6% | -6.2% | +73.4% | -4.0% | +17.6% | -4.6% | |
| – | – | +16.1% | -64.7% | +962.7% | -62.9% | -39.4% | +33.0% | +460.9% | -66.3% | -39.9% | +19.7% | |
| – | – | -12.8% | -21.4% | +401.4% | -5.4% | -8.1% | -6.6% | +74.1% | -4.6% | +17.7% | -4.9% | |
| – | – | -4.3% | -17.6% | +423.2% | -20.5% | +103.1% | -39.3% | +84.1% | +37.0% | +48.9% | -3.6% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | -96.2% | +2,575.0% | -93.1% | +0.6% | -5.3% | +16.9% | +2.1% | +27.0% | -6.1% | +76.4% | |
| – | – | +45.1% | +43.9% | +33.2% | +1.2% | -5.2% | +12.2% | +2.6% | +28.5% | -6.0% | +62.4% | |
| – | – | +2.6% | +3.2% | +2.5% | +3.0% | -24.0% | +6.2% | +11.6% | +11.7% | +3.5% | +254.5% | |
| – | – | +129.8% | +0.8% | +55.3% | +6.7% | -20.4% | +35.8% | -34.6% | -21.0% | +134.3% | -37.5% | |
| – | – | – | -241.2% | – | -5.1% | -8.6% | -6.9% | +76.8% | -4.7% | +18.6% | -6.4% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.0% | +4.8% | +0.0% | +0.0% | +0.0% | +0.1% | +0.1% | +2.2% | +6.7% | +27.6% | +2.4% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.